Sign inJoin waitlistJoin the waitlist

Taha Al-Juhaishi

Associate Program Director – Hematology and Oncology Fellowship · University of Oklahoma College of Medicine

Credentials: · · · · · · ·

History

Hematology and Oncology Fellowship · University of Oklahoma College of Medicine
Present
University of Oklahoma College of Medicine
Present

Hematology/Oncology Virginia Commonwealth University
2017–2020
Internal Medicine
Virginia Commonwealth University School of Medicine
2014–2017
University of Oklahoma Michael F. Price College
Weill Cornell Medicine-Qatar, Doha, Qatar
2010–2014

Research

Psychological factors: anxiety, depression, and somatization symptoms in low back pain patients
Journal of Pain Research · 2013 · 116 citations
Marginal Zone Lymphoma: State-of-the-Art Treatment
Review · Current Treatment Options in Oncology · 2019 · 52 citations
Cardiovascular disease research activity in the Middle East: a bibliometric analysis
Therapeutic Advances in Cardiovascular Disease · 2015 · 31 citations

Sadeer Al-Kindi
8 papers · 4 as a resident
Sairah Ahmed
8 papers
Rohtesh Mehta
6 papers
AL
Aleksandr Lazaryan
5 papers
Christopher Kanakry
5 papers
Filippo Milano
5 papers
Jennifer Kanakry
5 papers
Mohamad Khawandanah
5 papers
Sami Ibrahimi
5 papers
Shannon McCurdy
5 papers
Adam Asch
4 papers
Jennifer Saultz
4 papers

Clinical trials

Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Site PI · Recruiting · Phase 3
Eastern Cooperative Oncology Group
2025–2075
Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2024–2032
Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2023–2038
Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
Site PI · Recruiting · Phase 2
SWOG Cancer Research Network
2023–2029